Skip to main content
OpenTrials
Completed

NCT Number: NCT00681655

GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)

This study will assess whether the presence of a particular form of a gene, GABRA2, affects the functional responses of the human brain to alcohol administration and will evaluate that relationship in the context of factors known to increase the risk for future alcoholism.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–27 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital

Indianapolis, Indiana, 46202, United States

About this study

Each subject completed a total of 2 2.8 hr-long clamping sessions.Within each session, procedures differed only by the content of the infusate. In one session, 6% ethanol was infused. In the other session, only vehicle was infused, quantifying the placebo response for every subject. The order of alcohol or placebo sessions was counterbalanced; subjects were blind to which session was which; sessions were scheduled to occur approximately 2 weeks apart. Measures were collected before, and at beginning and end of infusion, and included subjective perceptions, EMG, EEG, stop-signal performance, eye movements, and auditory responses. Design allowed analysis of effect of alcohol vs placebo, initial effect of alcohol and acute tolerance to alcohol.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • European American male and females between 21-27 years of age.
  • Good health as determined by medical history, physical exam, and laboratory tests.
  • Females must have a negative urine pregnancy (hCG) test at the start of each study session.
  • People who consume 0.10 standard drinks per week (12 g-ethanol) per liter of total body water when averaged over the preceding month, or more, OR who have consumed more than 0.10 standard drinks per liter of total body water on any one occasion in the last month.

Exclusion criteria

  • Inability to read or comprehend eighth grade English.
  • Inability to hear or comprehend verbal instructions, or inability or unwillingness to cooperate with the procedures required for the study.
  • Inability to resolve 2 dots, each 2 mm in diameter with centers placed 5 mm apart on a card placed 20 inches from the bridge of the nose, or the need to wear eyeglasses to do so.
  • Current or prior history of any serious disease, including head trauma causing loss of consciousness, cancer, CNS, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, or alcohol or drug dependence, but not alcohol abuse or nicotine dependence.
  • Positive hepatitis or HIV test at screening, provided subject consented to these tests.
  • Current or prior history of alcohol-induced flushing reactions.
  • Current diagnosis of Axis-I psychiatric illness.
  • Positive result on urine drug screen obtained at the face-to-face interview.
  • Pregnancy, as determined by urine HcG on each day of laboratory testing, or intention to become pregnant for women.
  • Use of medications known to interact with alcohol within 2 weeks of the study.

Treatment and study plan

Alcohol

Other

Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).

Placebo

Other

Placebo (saline vehicle) infused for 2.8 hour long session.

Primary outcomes

  1. Effect of GABRA2 SNP status on AUD risk

    Time frame: Both session responses and lifetime traits will be included in analysis

    Results will assess the effect of GABRA2 SNPs on responses to alcohol and traits related to alcoholism risk

Secondary outcomes

  1. Acute tolerance to alcohol

    Time frame: Within 3 hour session

    Comparison of measures taken during the initial hour of the clamp with the same measures taken during the 3rd hour of the alcohol clamp.

  2. Initial response to alcohol

    Time frame: Within 3 hour session

    Comparison of measures taken during baseline with the same measures taken during the initial hour of the alcohol clamp.

  3. Responses to alcohol vs placebo

    Time frame: Within 3 hour session

    Measures taken during the alcohol session will either be compared to those taken during placebo, or in some cases measures taken during the alcohol session will be corrected for placebo effects by subtracting placebo responses from alcohol responses

Sponsors and collaborators

Lead sponsor

Indiana University

Other

Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Registry information

Acronym: GPRA

Important dates

Study start
2008
Primary completion
2012
Study completion
2012
First posted
May 21, 2008
Registry last updated
Apr 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.